Response to first TNFα inhibitors, percentage achieving response by ACR response criteria or decrease in disease activity by one DAS28-CRP or DAPSA28 category, along with availability of response calculations
| Improvement in clinical scores n (%) | 6 months | P value | 18 months | P value | ||
| Incl | Excl | Incl | Excl | |||
| ACR response available | 26 | 52 | 26 | 49 | ||
| ACR20 achieved | 20 (77%) | 31 (60%) | 0.25 | 18 (69%) | 29 (59%) | 0.55 |
| ACR50 achieved | 15 (58%) | 21 (40%) | 0.23 | 17 (65%) | 18 (37%) | 0.034 |
| ACR70 achieved | 7 (27%) | 12 (23%) | 0.93 | 13 (50%) | 14 (28%) | 0.11 |
| DAS28 available | 26 | 51 | 26 | 51 | ||
| Response by DAS28-CRP | 20 (77%) | 36 (71%) | 0.75 | 21 (81%) | 34 (67%) | 0.30 |
| DAPSA28 available | 23 | 46 | 24 | 49 | ||
| Response by DAPSA28 | 19 (83%) | 32 (70%) | 0.38 | 18 (75%) | 35 (71%) | 0.97 |
ACR20/50/70, American College of Rheumatology response criteria, improvement by 20%/50%/70%; DAPSA28, Disease Activity Score in Psoriatic Arthritis for 28 joints; DAS28, Disease Activity Score for 28 joints; DAS28-CRP, Disease Activity Score 28-joint count C reactive protein.